An overview of diabetes management in schizophrenia patients: Office based strategies for primary care practitioners and endocrinologists

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Annamalai, Aniyizhai ^a   Tek, Cenk ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; FLUPHENAZINE; HALOPERIDOL; HEMOGLOBIN A1C; METFORMIN; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; ZIPRASIDONE;

AGE DISTRIBUTION; APATHY; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIABETES MELLITUS; ENDOCRINOLOGIST; EVIDENCE BASED MEDICINE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GLUCOSE METABOLISM; HEALTH CARE PERSONNEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MOLECULAR DYNAMICS; MOTIVATION; NUTRITIONAL ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PHYSICAL ACTIVITY; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SOCIAL ISOLATION; SOCIAL STATUS;

EID: 84926624299     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/969182     Document Type: Article

References (54)

1. S. Brown, "Excessmortality of schizophrenia. A meta-analysis", The British Journal of Psychiatry, vol. 171, pp. 502-508, 1997.
2. C. W. Colton and R. W. Manderscheid, "Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states", Preventing Chronic Disease, vol. 3, no. 2, article A42, 2006.
3. A. J. Mitchell, D. Vancampfort, K. Sweers, R. Van Winkel, W. Yu, and M. De Hert, "Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis", Schizophrenia Bulletin, vol. 39, no. 2, pp. 306-318, 2013.
4. J. C. Ratliff, L. B. Palmese, E. L. Reutenauer, V. H. Srihari, and C. Tek, "Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness", Psychosomatics, vol. 54, no. 1, pp. 67-73, 2013.
5. C. G. Lyketsos, G. Dunn, M. J. Kaminsky, and W. R. Breakey, "Medical comorbidity in psychiatric inpatients relation to clinical outcomes and hospital length of stay", Psychosomatics, vol. 43, no. 1, pp. 24-30, 2002.
6. B. G. Druss, "Improving medical care for persons with serious mental illness: challenges and solutions", The Journal of Clinical Psychiatry, vol. 68, supplement 4, pp. 40-44, 2007.
7. B. G. Druss, S. C. Marcus, J. Campbell et al., "Medical services for clients in community mental health centers: results from a national survey", Psychiatric Services, vol. 59, no. 8, pp. 917-920, 2008.
8. H. E. Lester, J. Q. Tritter, and H. Sorohan, "Patients' and health professionals' views on primary care for people with serious mental illness: focus group study", The British Medical Journal, vol. 330, no. 7500, pp. 1122-1126, 2005.
9. H. Verdoux, M. Tournier, and B. Bégaud, "Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies", Acta Psychiatrica Scandinavica, vol. 121, no. 1, pp. 4-10, 2010.
10. J. M. Meyer, V. G. Davis, D. C. Goff et al., "Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1", Schizophrenia Research, vol. 101, no. 1-3, pp. 273-286, 2008.
11. V. H. Srihari, V. H. Phutane, B. Ozkan et al., "Cardiovascular mortality in schizophrenia: defining a critical period for prevention", Schizophrenia Research, vol. 146, no. 1.3, pp. 64-68, 2013.
12. H. A. Nasrallah, J. M. Meyer, D. C. Goff et al., "Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data fromthe CATIE schizophrenia trial sample at baseline", Schizophrenia Research, vol. 86, no. 1.3, pp. 15-22, 2006.
13. S. Saha, D. Chant, and J. McGrath, "A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?" Archives of General Psychiatry, vol. 64, no. 10, pp. 1123-1131, 2007.
14. M. De Hert, V. Schreurs, D. Vancampfort, and R. Van Winkel, "Metabolic syndrome in people with schizophrenia: a review", World Psychiatry, vol. 8, no. 1, pp. 15-22, 2009.
15. M. De Hert, R. Van Winkel, D. Van Eyck et al., "Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study", Clinical Practice and Epidemiology in Mental Health, vol. 2, article 14, 2006.
16. B. Kirkpatrick, B. J. Miller, C. Garcia-Rizo, E. Fernandez-Egea, and M. Bernardo, "Is abnormal glucose tolerance in antipsychotic-naïve patients with nonaffective psychosis confounded by poor health habits?" Schizophrenia Bulletin, vol. 38, no. 2, pp. 280-284, 2012.
17. B. G. Druss and B. J. Mauer, "Health care reform and care at the behavioral health. Primary care interface", Psychiatric Services, vol. 61, no. 11, pp. 1087-1092, 2010.
18. F. Rouillon and F. Sorbara, "Schizophrenia and diabetes: epidemiological data", European Psychiatry, vol. 20, supplement 4, pp. S345. S348, 2005.
19. L. W. Harris, P. C. Guest, M. T. Wayland et al., "Schizophrenia: metabolic aspects of aetiology, diagnosis and future treatment strategies", Psychoneuroendocrinology, vol. 38, no. 6, pp. 752-766, 2013.
20. M. De Hert, V. Schreurs, K. Sweers et al., "Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review", Schizophrenia Research, vol. 101, no. 1.3, pp. 295-303, 2008.
21. A. J. Mitchell, D. Vancampfort, A. De Herdt, W. Yu, and M. De Hert, "Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? a comparative meta-analysis of first episode, untreated and treated patients", Schizophrenia Bulletin, vol. 39, no. 2, pp. 295-305, 2013.
22. S. Mukherjee, D. B. Schnur, and R. Reddy, "Family history of type 2 diabetes in schizophrenic patients", The Lancet, vol. 1, no. 8636, article 495, 1989.
23. P. I. Lin and A. R. Shuldiner, "Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes", Schizophrenia Research, vol. 123, no. 2-3, pp. 234-243, 2010.
24. K. Brenner, A. Liu, D. P. Laplante et al., "Cortisol response to a psychosocial stressor in schizophrenia: blunted, delayed, or normal?" Psychoneuroendocrinology, vol. 34, no. 6, pp. 859-868, 2009.
25. A. S. Brown and E. S. Susser, "Prenatal nutritional deficiency and risk of adult schizophrenia", Schizophrenia Bulletin, vol. 34, no. 6, pp. 1054-1063, 2008.
26. J. McGrath, K. Saari, H. Hakko et al., "Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study", Schizophrenia Research, vol. 67, no. 2-3, pp. 237-245, 2004.
27. R. C. Andrews, "Diabetes and schizophrenia: genes or zinc deficiency", The Lancet, vol. 340, no. 8828, article 1160, 1992.
28. D. W. Haupt, "Differential metabolic effects of antipsychotic treatments", European Neuropsychopharmacology, vol. 16, supplement 3, pp. S149. S155, 2006.
29. I. C. Miron, V. C. Baroanə, F. Popescu, and F. Ionicə, "Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders", Current Health Sciences Journal, vol. 40, no. 1, pp. 12-17, 2014.
30. J. C. Ratliff, L. B. Palmese, E. L. Reutenauer, E. Liskov, C. M. Grilo, and C. Tek, "The effect of dietary and physical activity pattern onmetabolic profile in individualswith schizophrenia: a cross-sectional study", Comprehensive Psychiatry, vol. 53, no. 7, pp. 1028-1033, 2012.
31. S. Brown, J. Birtwistle, L. Roe, and C. Thompson, "The unhealthy lifestyle of people with schizophrenia", Psychological Medicine, vol. 29, no. 3, pp. 697-701, 1999.
32. M. Strassnig, J. S. Brar, and R. Ganguli, "Nutritional assessment of patients with schizophrenia: a preliminary study", Schizophrenia Bulletin, vol. 29, no. 2, pp. 393-397, 2003.
33. G. L. Daumit, R. W. Goldberg, C. Anthony et al., "Physical activity patterns in adults with severe mental illness", The Journal of Nervous and Mental Disease, vol. 193, no. 10, pp. 641-646, 2005.
34. F. Dickerson, C. R. Stallings, A. E. Origoni et al., "Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999.2011", Psychiatric Services, vol. 64, no. 1, pp. 44-50, 2013.
35. G. L. Daumit, F. B. Dickerson, N.-Y. Wang et al., "A behavioral weight-loss intervention in persons with seriousmental illness", The New England Journal of Medicine, vol. 368, no. 17, pp. 1594-1602, 2013.
36. C. A. Green, B. J. Yarborough, M. C. Leo et al., "The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial", The American Journal of Psychiatry, vol. 172, no. 1, pp. 71-81, 2015.
37. L. Chwastiak and C. Tek, "Management of obesity in the psychiatrist's office", World Psychiatry, vol. 13, no. 2, pp. 193-195, 2014.
38. J. M. Meyer and S. M. Stahl, "The metabolic syndrome and schizophrenia", Acta Psychiatrica Scandinavica, vol. 119, no. 1, pp. 4-14, 2009.
39. D. B. Allison, J. L. Mentore, M. Heo et al., "Antipsychoticinduced weight gain: a comprehensive research synthesis", The American Journal of Psychiatry, vol. 156, no. 11, pp. 1686-1696, 1999.
40. L. Maayan, J. Vakhrusheva, and C. U. Correll, "Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and metaanalysis", Neuropsychopharmacology, vol. 35, no. 7, pp. 1520-1530, 2010.
41. W. C. Knowler, E. Barrett-Connor, S. E. Fowler et al., "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin", The New England Journal of Medicine, vol. 346, no. 6, pp. 393-403, 2002.
42. M. Hasnain, S. K. Fredrickson, and W. V. R. Vieweg, "Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs", Journal of Psychopharmacology, vol. 25, no. 6, pp. 715-721, 2011.
43. A. Y. Khan, M. MacAluso, R. J. McHale, M. M. Dahmen, K. Girrens, and F. Ali, "The adjunctive use ofmetformin to treat or prevent atypical antipsychotic-induced weight gain: a review", Journal of Psychiatric Practice, vol. 16, no. 5, pp. 289-296, 2010.
44. R.-R. Wu, J.-P. Zhao, X.-F. Guo et al., "Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebocontrolled study", The American Journal of Psychiatry, vol. 165, no. 3, pp. 352-358, 2008.
45. R.-R. Wu, J.-P. Zhao, H. Jin et al., "Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial", The Journal of the American Medical Association, vol. 299, no. 2, pp. 185-193, 2008.
46. E. Carrizo, V. Fernández, L. Connell et al., "Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study", Schizophrenia Research, vol. 113, no. 1, pp. 19-26, 2009.
47. J. M. Gierisch, J. A. Nieuwsma, D. W. Bradford et al., "Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis", The Journal of Clinical Psychiatry, vol. 75, no. 5, pp. e424-e440, 2014.
48. A. Annamalai, L. B. Palmese, L. A. Chwastiak, V. H. Srihari, and C. Tek, "High rates of obstructive sleep apnea symptoms among patients with schizophrenia", Psychosomatics, vol. 56, no. 1, pp. 59-66, 2015.
49. M. Gitlin, "Lithium and the kidney: an updated review", Drug Safety, vol. 20, no. 3, pp. 231-243, 1999.
50. T. Baptista, N. M. K. N. Y. Kin, and S. Beaulieu, "Treatment of themetabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions", Clinical Pharmacokinetics, vol. 43, no. 1, pp. 1-15, 2004.
51. S. F. Ely, A. R. Neitzel, and J. R. Gill, "Fatal diabetic ketoacidosis and antipsychotic medication", Journal of Forensic Sciences, vol. 58, no. 2, pp. 398-403, 2013.
52. E.-H. Pok and W.-J. Lee, "Gastrointestinal metabolic surgery for the treatment of type 2 diabetes mellitus", World Journal of Gastroenterology, vol. 20, no. 39, pp. 14315-14328, 2014.
53. W. C. Steinmann, K. Suttmoeller, R. Chitima-Matsiga, N. Nagam, N. R. Suttmoeller, and N. A. Halstenson, "Bariatric surgery:1-year weight loss outcomes in patients with bipolar and other psychiatric disorders", Obesity Surgery, vol. 21, no. 9, pp. 1323-1329, 2011.
54. A. T. Ahmed, E. M. Warton, C. A. Schaefer, L. Shen, and R. S. Mcintyre, "The effect of bariatric surgery on psychiatric course among patients with bipolar disorder", Bipolar Disorders, vol. 15, no. 7, pp. 753-763, 2013.